Avidity Biosciences, Inc. (RNA)
|52 Week Range||9.83-25.74|
|1y Target Est||-|
|DCF Unlevered||RNA DCF ->|
|DCF Levered||RNA LDCF ->|
|Debt / Equity||10.50%||Neutral|
Upgrades & Downgrades
Latest RNA news
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates
9 May 2023
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.71 per share a year ago.
Avidity (RNA) Down on Update From Neuromuscular Disease Study
31 March 2023
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
Avidity Bio Crashes 26% After 'Rarer Than Rare' Event Sidelines Key Study
30 March 2023
A key study from Avidity Biosciences remains on hold after a patient experienced a rare side effect, leading RNA stock to plummet Thursday. The post Avidity Bio Crashes 26% After 'Rarer Than Rare' Eve...
Avidity's stock falls after sharing additional data about partial clinical hold
30 March 2023
Shares of Avidity Biosciences Inc. RNA, +0.55% fell about 3.0% in premarket trading on Thursday after the company said a partial clinical hold on its experimental treatment for adults with myotonic dy...
Avidity Biosciences: Helping Deliver Oligonucleotides Outside Liver Cells
9 March 2023
Avidity Biosciences, Inc. is a leader in antibody Oligonucleotide conjugate technology. This technology enables delivery of Oligonucleotides to muscles and other tissues.
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
28 February 2023
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -4.76% and 15.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the s...
5 Best and Worst Performing Small-Cap Stocks in Dec 2022
17 January 2023
Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.
Avidity Biosciences Will Rise As It Revolutionizes The Field Of RNA Therapeutics
23 December 2022
Avidity Biosciences possesses the only RNA agent capable of being delivered into the muscle. The company's platform success opens up its pipeline to rare muscle diseases and previously unreachable tis...
Avidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technology
22 December 2022
Avidity Biosciences' stock was up 55% last week after releasing preliminary data from a Phase 1/ 2 study of its antibody-oligonucleotide technology candidate in treating myotonic dystrophy type 1. The...
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >